Gavi: The Vaccine Alliance
April 18, 2013
The cost of immunising millions of the world’s most vulnerable children against five deadly and debilitating diseases is set to fall, thanks to a major price reduction of one third for pentavalent vaccine.
This new, more cost-effective price provides the opportunity for the GAVI Alliance to pay up to US$ 150 million less over the next four years compared with using lowest cost alternative suppliers.
A supply agreement with Biological E Ltd of India makes the five-in-one shot available to GAVI for just $1.19 per dose, compared to the 2012 weighted average price of $2.17.